Medical devices

Covid-19 coronavirus: patent database observations

Lars Braams

As per 8 September 2020, 143 search results containing the words “Covid 19” in the title, claims or the abstract of a patent show up in the international patent database Espacenet. Over the past weeks, this number grows with about 15 new results each week. While the race for a vaccine covers the headlines around Read More

Covid-19 – Coronavirus: French Health Ministry publishes orders and decrees concerning serological tests assessments, listings and reimbursements

Eveline Van Keymeulen

Further to the previous publications by the French High Health Authority (HAS), the French Health Ministry published on 21 May 2020 the list of serological tests deemed reliable and validated by the National Reference Centre for respiratory infection viruses (CNR) on its Covid-19 platform (see our previous post here). On the same date, a new Read More

Belgium: Covid-19 – Coronavirus: serological tests now available

Tine Carmeliet

Certain serological tests for Covid-19 have been made available to the public in Belgium. The tests examine for the presence of antibodies against Covid-19 and enable patients to know whether they have been infected in the past. On 13 May 2020, a Royal Decree on temporary measures in the fight against the Covid-19 pandemic and Read More

Advocate General of the CJEU considers French ban on hemp-derived cannabidiol (CBD) contrary to EU law

Eveline Van Keymeulen

Yesterday, Advocate General Tanchev presented his long-awaited opinion before the Court of Justice of the European Union (CJEU) in Case C-663/18 (Kanavape) stating that the general ban on natural cannabidiol (CBD) in France is contrary to EU law. It is the first time that the highest European Court, including the Advocate General, has been requested Read More

Covid-19 coronavirus: EMA Fast Track Procedures for Medicines and Vaccines

Rafi Allos

The European Medicines Agency (EMA) announced on 4 May that the EMA will accelerate regulatory procedures for supporting R&D of, and evaluating marketing authorisation applications (MAAs) for, medicines and vaccines for Covid-19 coronavirus.  Further details regarding these measures are in an inventory published with the announcement.  These measures are available both for new medicines and Read More